Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species

Medical Mycology

Volumn 39, Issue 1, 2001, Pages 91-95

  Ryder, N S ^a   Leitner, I ^a  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

Aspergillus; Synergy; Terbinafine; Triazoles

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER;

EID: 0035123039     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/714030977     Document Type: Article

References (29)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
2. Ellioti MW, Taylor AJN. Allergic bronchopulmonary aspergillosis. Clin Exp Allergy 1997; 27 (Suppl. 1): 55-59.
3. Ryder NS, Favre B. Antifungal activity and mechanism of action of terhinafine. Rev Contemp Pharmacother 1997; 8: 275-287.
4. Schiraldi OF, Colombo MD. Potential use of terbinafine in the treatment of aspergillosis. Rev Contemp Pharmacother 1997; 8: 349-356.
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS Document M27-A. Wayne, PA: NCCLS, 1997.
6. Ryder NS. Wagner S. Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42: 1057-1061.
7. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978; 137: 122-130.
8. Hitchcock CA. Pye GW, Oliver GP, et al. UK-109,496: a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco. 17-20 September 1995. Washington DC: American Society for Microbiology, 1995. Abstract F72.
9. Petranyi G, Meingassner JG. Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365-1368.
10. Clayton YM. The in vitro activity of terbinafine against uncommon fungal pathogens. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: J.R. Prous Science Publishers, 1987: 433-439.
11. Schmitt HJ, Bernard EM. Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988:32:780-781.
12. Mikami Y. Yazawa K, Uno J, Nishimura K. Comparison of antifungal activity of amphotericin B. miconazole. itraconazole, flucytosine and fluconazole against clinically isolated Crvptococcus neoformans by MIC and ICso values, and their combination effects. Chemotherapy (Tokyo) 1991; 39: 1-8.
13. Martin E, Maier F. Bhakdi S. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 1994; 38: 1331-1338.
14. Schaffner A. Böhler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993: 36: 421-424.
15. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing. Antimicrob Agents Chemother 1995; 39: 1907-1912.
16. Norden G, Bjorck S, Persson H, et al. Cure of zygomycosis caused by a lipase-producing Rhizopns rhizopodiformis strain in a renal transplant patient. Scand J Infect Dis 1991; 23: 377-382.
17. Stiller MJ, Teperman L. Rosenthal SA, et al. Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol 1994; 31: 344-347.
18. Kirkpalrick WR, McAtee RK. Ryder NS, Patterson TF. Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemolherapv. San Diego, 24-27 September 1998. Washington DC: American Society for Microbiology, 1998: Abstract J77.
19. Barrett-Bee K, Ryder NS. Biochemical aspects of ergosterol biosynthesis inhibition. In: Sutcliffe JA, Georgopapadakou NH. eds. Emerging Targets for Antibacterial and Am/fungal Chemotherapy. New York: Chapman and Hall, 1992: 410-436.
20. Fothergill AW, Leitner I, Meingassner JG. et al. Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazole. Abstracts of the 36th Inlerscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 15-18 September 1996. Washington DC: American Society for Microbiology. 1996: Abstract E53.
21. Ryder NS. Leitner I. Synergy between terbinafine and fluconazole against azole- and multidrug-resistant Candida isolates. Abstracts of the 37th Inlerscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 28 September-1 October 1997. Washington DC: American Society for Microbiology. 1997: Abstract E-70.
22. Barchiesi F, Di Francesco LF. Scalisc G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azolcs. Antimicrob Agents Chemother 1997; 41: 1812-1814.
23. Engelkens HJH, Naafs B. Mycetoma. Br J Dermatol 1994; 131: 722-723.
24. Cox NH, Irving B. Cutaneous 'ringworm' lesions of Scopulariopsis brevicaulis. Br J Dermatol 1993; 129: 726-728.
25. Anaissie EJ, Kontoyiannis DP. Hüls C. et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172: 599-602.
26. Del Sorbo G, Andrade AC. Van Nistelrooy JGM, et al. Multidrug resistance in Aspergillus nidulans involves novel ATP-binding cassette transporters. Mol Gen Genet 1997: 254: 417-426.
27. Schiraldi GF, Colombo MD, Harari S, et al. Terbinafine in the treatment of non-immunocompromised compassionate cases of bronchopulmonary aspergillosis. Mycoses 1996; 39: 5-12.
28. Harari S. Schiraldi G, De Juli E, Gronda E. Relapsing Aspergillus bronchitis in a double lung transplant patient, successfully treated with a new oral antimycotic agent. Chest 1997:111:835-836.
29. Beytout J, Cambon M, Demeocq F, el al. Terbinafine (Lamisil) in the treatment of invasive aspergillosis. Abstracts of Focus on Fungal Infections 8. Alpharetta, G A, 4-6 March 1998. Orlando. FL: Imedex USA Inc., 1998.